You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 1
  • 5PSQ-041 Safety and efficacy of high doses of irinotecan in patients with metastatic colorectal cancer treated with FOLFIRI scheme based on UGT1A1 genotype: a systematic review

Article info

Article menu

Download PDFPDF

Section 5: Patient safety and quality assurance
5PSQ-041 Safety and efficacy of high doses of irinotecan in patients with metastatic colorectal cancer treated with FOLFIRI scheme based on UGT1A1 genotype: a systematic review
Free

Authors

Citation

Miarons M, Riera-Armengol P, García-Gil S, et al
5PSQ-041 Safety and efficacy of high doses of irinotecan in patients with metastatic colorectal cancer treated with FOLFIRI scheme based on UGT1A1 genotype: a systematic review
European Journal of Hospital Pharmacy 2022;29:A131-A132.

Publication history

  • First published March 23, 2022.
Online issue publication 
April 22, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.